Kailera broke records with its $625 million IPO in April. But its high-water mark didn’t last long — in June, Parabalis made a $670 million debut, putting its own name on top of the record books. On Post-Hoc Live, we’re joined by Ron Renaud and Mathai Mammen, the CEOs of the companies, to talk about what it took to reach those heights. 

Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D